文献速递乳腺癌放疗

缺医少药人群中每周一次大分割乳腺照射的患者报告结局与美容效果

Patient-Reported Outcomes and Cosmesis After Once-Weekly Hypofractionated Breast Irradiation in Medically Underserved Patients.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-05-06

该2期试验评估保乳术后每周一次大分割乳腺照射(WH-WBI)的患者报告结局与美容效果。158例0-II期乳腺癌患者接受28.5-30 Gy/5次照射,中位随访39.3个月,148例可分析。6个月时整体BCTOS评分、乳房疼痛和手臂功能出现短暂恶化后恢复,但美容子评分持续变差且1年和3年无显著改善;医生评估3年美容优良率89%。

要点

  • WH-WBI后6个月整体BCTOS、乳房疼痛及手臂功能恶化,1年和3年恢复至接近基线。
  • BCTOS美容子评分6个月恶化后持续存在,1年和3年无显著改善,多为轻中度。
  • 医生评估3年美容效果优良89%、一般/差11%。

核心结论

  • WH-WBI与手臂功能和乳房疼痛的短暂恶化相关,但美容PROs存在持续不良变化,通常为轻中度。
  • 医生评估的美容效果可接受。

研究设计与样本

  • 2期试验,纳入2011至2015年158例接受保乳术且切缘阴性的0-II期乳腺癌女性,148例可分析。
  • WH-WBI方案为28.5至30 Gy分5次每周照射,每次5.7至6 Gy,可联合或不联合推量。
  • 采用BCTOS和QLQ-BR23收集治疗后3年PROs,医生用Global Cosmesis Score评估美容效果,纵向增长模型分析BCTOS变化。

主要发现

  • 中位随访39.3个月,放疗后6个月整体BCTOS评分、乳房疼痛和手臂功能子评分出现不良变化(P < .001),1年和3年改善至接近基线。
  • BCTOS美容子评分在6个月时也出现不良变化(P < .001),1年(P = .385)和3年(P = .644)无显著改善。
  • 未检测到年龄、体重指数、糖尿病、吸烟、乳房体积、肿瘤大小、血清肿体积、剂量学因素、剂量、推量或全身治疗对BCTOS纵向变化的影响。
  • 医生评估3年美容效果优良89%、一般/差11%。

关键数值与推荐

  • WH-WBI剂量:28.5至30 Gy分5次每周照射,每次5.7至6 Gy,可联合或不联合推量。
  • 6个月整体BCTOS、乳房疼痛、手臂功能及美容子评分不良变化P < .001;美容子评分1年P = .385、3年P = .644。
  • 3年医生评估美容优良率89%,一般/差11%。

临床怎么用

  • 对医学资源不足人群可考虑每周一次大分割乳腺照射,但需告知美容PROs可能持续变差。
  • 治疗后应关注手臂功能和乳房疼痛,多数为短暂恶化并在1年内恢复。
  • 医生评估美容效果可接受,但患者报告的美容变化可能持续存在,需长期随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate patient-reported outcomes (PROs) and cosmesis from a phase 2 trial of once-weekly hypofractionated breast irradiation (WH-WBI) after breast-conserving surgery (BCS). METHODS AND MATERIALS: Patients had stage 0-II breast cancer treated with BCS and negative margins. WH-WBI was 28.5 to 30 Gy in 5 weekly fractions of 5.7 to 6 Gy delivered with or without a boost. PROs were collected for 3 years after treatment using the Breast Cancer Treatment Outcome Scale (BCTOS) and European Organization for Research and Treatment of Cancer Breast Cancer-Specific Quality of Life Questionnaire (QLQ-BR23). Physicians rated cosmetic outcome with the Global Cosmesis Score. Longitudinal growth models were used to assess changes in BCTOS across time, and baseline values and changes between time points were correlated with patient and treatment factors. RESULTS: From 2011 to 2015, 158 women received WH-WBI, and 148 were eligible for analysis after a median follow-up of 39.3 months. Adverse changes (P < .001) in global BCTOS score and breast pain and arm function subscores were observed 6 months after radiation therapy, followed by improvement to near-baseline values at years 1 and 3. Adverse changes in BCTOS cosmetic subscore were also detected at 6 months (P < .001), with no significant improvement at 1 (P = .385) and 3 (P = .644) years. No effect was detected for longitudinal changes in BCTOS scoring for age, body mass index, diabetes, smoking, breast volume, tumor size, seroma volume, dosimetric factors, dose, boost, or systemic therapy. Physician-rated cosmesis at 3 years was excellent/good in 89% and fair/poor in 11%. CONCLUSIONS: WH-WBI was associated with transient worsening in arm function and breast pain but persistent adverse changes in cosmetic PROs that were typically mild or moderate in severity. Physician-rated cosmetic outcomes were acceptable.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Eldredge-Hindy H, Gaskins J, Dragun A, et al. Patient-Reported Outcomes and Cosmesis After Once-Weekly Hypofractionated Breast Irradiation in Medically Underserved Patients. Int J Radiat Oncol Biol Phys. 2020. PMID: 32387804. doi:10.1016/j.ijrobp.2020.04.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。